(P-387) Evaluation of Treatment Satisfaction and Experiences Among People With HIV When Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide From Cabotegravir + Rilpivirine: Results From the Phase 4 EMPOWER Study

Monday, October 20, 2025

12:15 PM - 1:30 PM US ET

Location: Poster Hall B4-B5

Presenting Author(s)

Samir K. Gupta, MD (he/him/his)

Professor of Medicine
Indiana University School of Medicine
Indianapolis, IN, United States

TM

Thomas CS Martin, MD

Assistant Professor of Medicine
University of California San Diego
La Jolla, California, United States
CG

Cyril Gaultier, MD

BIOS Clinical Research
Palm Springs, California, United States
AK

Alexandra Kissling, PhD

Oracle Life Sciences
Austin, Texas, United States
KB

Kathleen Beusterien, MPH

Oracle Life Sciences
Austin, Texas, United States
MC

Megan Chen, MSPH

Gilead Sciences, Inc.
Foster City, California, United States
MD

Megan Dunbar, PhD (she/her/hers)

Executive Director, Global Medical Affairs
Gilead Sciences
Forest City, CA, United States
HL

Hui Liu, PhD

Director
Gilead Sciences, Inc., Foster City, CA, USA
Foster City, California, United States
BN

Brenda Ng, PhD

Gilead Sciences, Inc.
Foster City, California, United States
Moti Ramgopal, MD

Medical Director
Midway Immunology and Research Center
Fort Pierce, Florida, United States